From: Nanomedicine review: clinical developments in liposomal applications
References | Years | Phase | Disease | LF | n | Dose | Efficacy | ||
---|---|---|---|---|---|---|---|---|---|
ORR (%) | m-PFS (months) | m-OS (months) | |||||||
Wang and Zhang (2014) | 2014 | II | NSCLC | LPTX + carboplatin | 27 | 175 mg/m2 | 44.4 | 6 | – |
Lu et al. (2015) | 2015 | II | NSCLC | LPTX + gemcitabine + carboplatin | 48 | 3 mg/ml IT + 1000 mg/m2 IV day 1 and 8 + 5 AUC IV day 1 Q3W | 81 | 16.5 | 23.2 |
Ahn et al. (2014) | 2014 | II | NSCLC | Genexol-PM + gemcitabine |  | 230 mg/m2 day 1 + 1000 mg/m2 days 1 and 8 IV Q3W | 46.5 | 4 | 14.8 |
Hu et al. (2013)a | 2013 | II | NSCLC | LPTX + cis-platin | 63 | 135 mg PTX/m2 to 175 mg PTX/m2 | – | – | – |
Ignatiadis et al. (2016) | 2016 | I | BC | EndoTAG-1 + PTX + fluorouracil + epirubicin + cyclophosphamide | 15 | 22 mg/m2 + 70 mg/m2 IV Q1W + 500 mg/m2 + 100 mg/m2 + 500 mg/m2 Q3W | 33 | – | – |
Awada et al. (2014) | 2014 | II | TNBC | EndoTAG-1 + PTX | 56 | 22 mg/m2 + 70 mg/m2 Q1W | 45 | 3.7 | 13.0 |
EndoTAG-1 | 58 | 88Â mg/m2 Q1W | 25 | 3 | 11.9 | ||||
Lu et al. (2016) | 2016 | II | AGC | LPTX + capecitabine | 34 | 135 mg/m2 IV day 1 + 2000 mg/m2 PO days 1–14 Q3W | 47 | 6.9 | 12.5 |
Xu et al. (2013) | 2013 | II | MGC | Lipusu® | 30 | 135 mg/m2 IV day 1 | 47 | – | – |
Haas et al. (2012) | 2012 | II | PC | EndoTAG-1 + Gem | 50 | 11 mg/m2 | 14 | 4.1 | 8.1 |
50 | 22Â mg/m2 | 14 | 4.6 | 8.7 | |||||
5 | 44Â mg/m2 | 16 | 4.4 | 9.3 | |||||
Graziani et al. (2017) | 2017 | II | EOC | PTX–LCN | 14 | 175 mg/m2 | – | 3 | – |
Strieth et al. (2013)b | 2013 | I | HNC | EndoTAG-1 | 5 | 1.1 mg PTX/kg | – | – | – |
Slingerland et al. (2017)b | 2013 | II | AC | LEP-ETU | 30 | 175 mg PTX/m2 Q3W | – | – | – |